In the prediction of response to sorafenib, Horwitz et al. suggested that amplification of VEGF-A in HCC may be useful since they observed that patients with VEGF-A amplification have an increased tumor sensitivity to this treatment [111]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.